Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells
Year: 2012
Type: article
Source: Blood
Authors: Jason A Dubovsky, Kyle A Beckwith, Jennifer A. Woyach, Samantha M. Jaglowski, Joshua Hessler, Betty Y. Chang, Karilyn Larkin, Matthew R Stefanovski, Frank W Frissora, Lisa L. Smith, Kelly A Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A Andritsos, Kami Maddocks, Amy Lehman, Richard R. Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Joseph J. Buggy, Natarajan Muthusamy, Amy J Johnson, John C. Byrd
Institutions: The Ohio State University Wexner Medical Center, The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Pharmacyclics (United States), Cornell University, Weill Cornell Medicine, The US Oncology Network
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2593681673